Leflunomid Stada (Leflunomide)

Leflunomide is metabolized to teriflunomide, an inhibitor of dihydroorotate dehydrogenase. By blocking this enzyme, the drug reduces pyrimidine synthesis, limiting the proliferation of activated T‑cells and other lymphocytes, thereby dampening the autoimmune response that drives joint and skin inflammation.

The dosing regimen for Leflunomid Stada is individualized by the prescribing clinician based on the patient’s disease severity, response, and laboratory monitoring. No fixed dose can be stated here; the prescriber sets the appropriate dose and titration schedule.

Leflunomid Stada is contraindicated in pregnancy (Category X) because of a high risk of fetal malformations. It is also not recommended for breastfeeding mothers, as the drug can be excreted in milk and may affect the infant.

To request Leflunomid Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

The primary alternative to leflunomide is methotrexate, another disease‑modifying antirheumatic drug. While both reduce disease activity, leflunomide is taken orally once daily and has a different safety profile, notably a higher risk of liver enzyme elevation and teratogenicity, whereas methotrexate carries a risk of pulmonary toxicity and requires folic acid supplementation.

Leflunomid Stada should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Leflunomid Stada is administered orally, typically as a tablet taken with or without food. The exact dosing schedule is determined by the prescribing physician, and patients should follow the instructions on the prescription label.

Serious risks include severe liver injury, bone‑marrow suppression leading to anemia or low white‑cell counts, teratogenic effects if pregnancy occurs, and opportunistic infections. Patients should report signs of jaundice, unusual bruising, persistent fever, or any pregnancy‑related concerns to their healthcare provider promptly.

Leflunomid Stada should not be used by pregnant women, individuals with severe liver disease, those with active infections, or patients who are unable to use effective contraception. Caution is also advised for patients with significant renal impairment or a history of hypersensitivity to leflunomide.